Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

BACKGROUND: Sunitinib malate (SUTENT) has promising single-agent activity given on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off treatment) in advanced non-small cell lung cancer (NSCLC). METHODS: We examined the activity of sunitinib on a continuous daily dosing (CDD) schedule in an op...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Novello, S, Scagliotti, G V, Rosell, R, Socinski, M A, Brahmer, J, Atkins, J, Pallares, C, Burgess, R, Tye, L, Selaru, P, Wang, E, Chao, R, Govindan, R
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2009
Assuntos:
Clinical Study
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2778527/
https://ncbi.nlm.nih.gov/pubmed/19826424
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605346
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares